Chunxiao Wei, Guimei Zhang, Xiaoshu Fu, Meng Zhao, Weijie Zhai, Yanxin Shen, Li Sun
{"title":"血清Olfactomedin 4与阿尔茨海默病的相关性研究","authors":"Chunxiao Wei, Guimei Zhang, Xiaoshu Fu, Meng Zhao, Weijie Zhai, Yanxin Shen, Li Sun","doi":"10.1007/s12035-025-04812-w","DOIUrl":null,"url":null,"abstract":"<p><p>Olfactomedin 4 (OLFM4) plays important roles in inflammation, immune regulation, apoptosis, and neurodevelopment. This study aimed to investigate the correlation of serum OLFM4 with Alzheimer's disease (AD) and its clinical phenotype in different apolipoprotein E (APOE) ε4 status. Serum OLFM4 levels were measured in 122 AD patients and 113 healthy controls (HC). Correlations between OLFM4 levels and cognitive function and brain volume were analyzed in the context of APOE ε4 status. Multivariate logistic regression modeling was used to assess the contribution of high OLFM4 levels and APOE ε4 status to the risk of AD. It turns out that serum OLFM4 levels were significantly higher in patients with AD than in HC and were associated with APOE ε4 status but not sex. Serum OLFM4 levels showed a dose-response relationship with cognitive function and were correlated with brain atrophy. The combination of high OLFM4 levels and APOE ε4 expression was a risk factor for AD (odds ratio = 5.440; p = 0.017). In conclusion, serum OLFM4 may be involved in the pathology of AD and holds promise as a potential biomarker of AD as well as a therapeutic target. And the effects of OLFM4 for AD may be mediated by APOE ε4.</p>","PeriodicalId":18762,"journal":{"name":"Molecular Neurobiology","volume":" ","pages":"8900-8911"},"PeriodicalIF":4.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Apolipoprotein E ε4-Specific Relationship Between Serum Olfactomedin 4 and Alzheimer's Disease.\",\"authors\":\"Chunxiao Wei, Guimei Zhang, Xiaoshu Fu, Meng Zhao, Weijie Zhai, Yanxin Shen, Li Sun\",\"doi\":\"10.1007/s12035-025-04812-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Olfactomedin 4 (OLFM4) plays important roles in inflammation, immune regulation, apoptosis, and neurodevelopment. This study aimed to investigate the correlation of serum OLFM4 with Alzheimer's disease (AD) and its clinical phenotype in different apolipoprotein E (APOE) ε4 status. Serum OLFM4 levels were measured in 122 AD patients and 113 healthy controls (HC). Correlations between OLFM4 levels and cognitive function and brain volume were analyzed in the context of APOE ε4 status. Multivariate logistic regression modeling was used to assess the contribution of high OLFM4 levels and APOE ε4 status to the risk of AD. It turns out that serum OLFM4 levels were significantly higher in patients with AD than in HC and were associated with APOE ε4 status but not sex. Serum OLFM4 levels showed a dose-response relationship with cognitive function and were correlated with brain atrophy. The combination of high OLFM4 levels and APOE ε4 expression was a risk factor for AD (odds ratio = 5.440; p = 0.017). In conclusion, serum OLFM4 may be involved in the pathology of AD and holds promise as a potential biomarker of AD as well as a therapeutic target. And the effects of OLFM4 for AD may be mediated by APOE ε4.</p>\",\"PeriodicalId\":18762,\"journal\":{\"name\":\"Molecular Neurobiology\",\"volume\":\" \",\"pages\":\"8900-8911\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Neurobiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12035-025-04812-w\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Neurobiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12035-025-04812-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Apolipoprotein E ε4-Specific Relationship Between Serum Olfactomedin 4 and Alzheimer's Disease.
Olfactomedin 4 (OLFM4) plays important roles in inflammation, immune regulation, apoptosis, and neurodevelopment. This study aimed to investigate the correlation of serum OLFM4 with Alzheimer's disease (AD) and its clinical phenotype in different apolipoprotein E (APOE) ε4 status. Serum OLFM4 levels were measured in 122 AD patients and 113 healthy controls (HC). Correlations between OLFM4 levels and cognitive function and brain volume were analyzed in the context of APOE ε4 status. Multivariate logistic regression modeling was used to assess the contribution of high OLFM4 levels and APOE ε4 status to the risk of AD. It turns out that serum OLFM4 levels were significantly higher in patients with AD than in HC and were associated with APOE ε4 status but not sex. Serum OLFM4 levels showed a dose-response relationship with cognitive function and were correlated with brain atrophy. The combination of high OLFM4 levels and APOE ε4 expression was a risk factor for AD (odds ratio = 5.440; p = 0.017). In conclusion, serum OLFM4 may be involved in the pathology of AD and holds promise as a potential biomarker of AD as well as a therapeutic target. And the effects of OLFM4 for AD may be mediated by APOE ε4.
期刊介绍:
Molecular Neurobiology is an exciting journal for neuroscientists needing to stay in close touch with progress at the forefront of molecular brain research today. It is an especially important periodical for graduate students and "postdocs," specifically designed to synthesize and critically assess research trends for all neuroscientists hoping to stay active at the cutting edge of this dramatically developing area. This journal has proven to be crucial in departmental libraries, serving as essential reading for every committed neuroscientist who is striving to keep abreast of all rapid developments in a forefront field. Most recent significant advances in experimental and clinical neuroscience have been occurring at the molecular level. Until now, there has been no journal devoted to looking closely at this fragmented literature in a critical, coherent fashion. Each submission is thoroughly analyzed by scientists and clinicians internationally renowned for their special competence in the areas treated.